Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoSTU:CUP -5.35%95 Return-on-Tangible-Asset is 20.15% as of Jun. 2026, which is 11% above its 10-year median of 18.09. GuruFocus rates STU:CUP with a GF Score™ of 95/100 and a GF Value™ of €42.02 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,009 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 94.45% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Chugai Pharmaceutical Co's annualizedNet Income for the quarter that ended in Jun. 2026 was €2,512 Mil. Chugai Pharmaceutical Co's average total tangible assets for the quarter that ended in Jun. 2026 was €12,468 Mil. Therefore, Chugai Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 20.15%.
The historical rank and industry rank for Chugai Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
STU:CUP'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.87 Med: 18.09 Max: 22.28
Current: 20.66
During the past 13 years, Chugai Pharmaceutical Co's highest Return-on-Tangible-Asset was 22.28%. The lowest was 6.87%. And the median was 18.09%.
STU:CUP's Return-on-Tangible-Asset is ranked better than 94.45% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs STU:CUP: 20.66
Chugai Pharmaceutical Co (STU:CUP) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Chugai Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Chugai Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Chugai Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co Return-on-Tangible-Asset Chart
STU:CUP vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 20.15% mean?
Chugai Pharmaceutical Co (STU:CUP) has a Return-on-Tangible-Asset of 20.15% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Chugai Pharmaceutical Co and its competitors. This is 11% above median its historical median of 18.09. Over the past decade, Chugai Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 6.87 to 22.28. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #56 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 5.6%.
Is Chugai Pharmaceutical Co's Return-on-Tangible-Asset too high?
Chugai Pharmaceutical Co's current Return-on-Tangible-Asset of 20.15% is 11% above median its 10-year median of 18.09. Over the past 10 years, this metric has ranged from a low of 6.87 to a high of 22.28. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.13. Chugai Pharmaceutical Co's value of 20.15% is 543.8% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #56 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #56 out of 1009 companies for Return-on-Tangible-Asset. This places Chugai Pharmaceutical Co in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.13. Chugai Pharmaceutical Co's value of 20.15% is 543.8% above this benchmark. Historically, Chugai Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 6.87 to 22.28 over the past decade. While the company's 10-year median is 18.09 vs. the industry median of 3.13, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.13, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Return-on-Tangible-Asset of 20.15% is 543.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Return-on-Tangible-Asset is 20.15%, which is 11% above median its own 10-year median of 18.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (STU:CUP) is currently considered Modestly Undervalued. The stock's GF Value™ is €42.02, compared to a current price of €36.79 — trading 12.4% below its estimated fair value. The current Return-on-Tangible-Asset is 20.15%, which is 11% above median its 10-year median of 18.09 and 543.8% above the Drug Manufacturers industry median of 3.13. Chugai Pharmaceutical Co's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Chugai Pharmaceutical Co (STU:CUP), the current Return-on-Tangible-Asset is 20.15% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (STU:CUP) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of €36.79 is trading 12.4% below its estimated GF Value™ of €42.02.
GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for STU:CUP:
Return-on-Tangible-Asset: 20.15% (11% above median its 10-year median of 18.09)
GF Value™: €42.02 vs. price of €36.79 (12.4% below fair value)
Industry Position: 543.8% above the Drug Manufacturers median (#56 of 1009)
No single metric tells the full story. See the STU:CUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
95GF Score
Get the complete analysis for STU:CUP
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CUP has been successfully added to your 
